Clinical Research Directory
Browse clinical research sites, groups, and studies.
Probiotics and Insulin Resistance in Obese Asthmatics
Sponsor: University of Alabama at Birmingham
Summary
In this pilot study investigators will test the hypothesis that administration of oral probiotics modulates microbiome/metabolome, lowers leptin and insulin resistance and improves clinical parameters of asthma in obese insulin resistant asthmatics. Preliminary studies with oral probiotic administration in obese asthmatics showed increased abundance of probiotics-derived Bifidobacterium species and Bifidobacterium-derived metabolite in the airways of asthmatics. Additionally, neutrophils and IL-17 producing Th17 cells were significantly reduced following probiotics administration. Based on these preliminary studies, the investigators propose to test the following aims: Specific Aim 1: Determine if probiotic administration modulates airway microbiome/metabolome in obese insulin resistant asthmatics Specific Aim 2: Determine if modulation of leptin levels and insulin sensitivity by probiotics administration correlates with airway metabolome alterations and weight loss in obese insulin resistant asthmatics Specific Aim 3: Determine if microbiome/metabolome changes in probiotics group correlates with changes in asthma biomarkers and improved clinical outcomes compared to placebo in obese insulin resistant asthmatics.
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2024-04-01
Completion Date
2026-06-30
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
Probiotic
10 subject will receive a probiotic daily for 12 weeks.
Placebo
10 subjects will receive a placebo daily for 12 weeks.
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States